Solid Tumor, Lung Cancer
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
The results of this study are not yet available.
The duration of your participation depends on how well your disease responds to the study treatment.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participant must have a diagnosis of cancer (confirmed by histology or cytology) that is not responsive to other treatments
- Participant must be willing to undergo tumor biopsies during the study